Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Psoriasis 2Lymphoma, Follicular 2Spondylitis, Ankylosing 1Periodic Fevers Syndrome 1Motor Activity 1Melanoma 1Crohn Disease 1Colorectal Neoplasms 1Arthritis, Rheumatoid 1

Interventions

tofacitinib 7Etanercept 6Methotrexate 3Adalimumab 3secukinumab 2Nivolumab 2sotrastaurin 1sodium luminolate 1ixekizumab 1deucravacitinib 1calcipotriene 1cabozantinib 1baricitinib 1apremilast 1abrocitinib 1Vitamin D 1Vaccines 1Specimen Handling 1Saline Solution 1Platinum Compounds 1Ipilimumab 1Herpes Zoster Vaccine 1Folic Acid 1Fish Oils 1Fatty Acids, Omega-3 1Exercise 1Eicosapentaenoic Acid 1Docosahexaenoic Acids 1Cholecalciferol 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Psoriasis × secukinumab × Clear all
NCT04571567 2022-04-11

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

Icahn School of Medicine at Mount Sinai

Phase 4 Completed
20 enrolled
Lymphoid

Lymphoma, Follicular, Psoriasis

NCT01961609 2019-03-18

SIGNATURE

Novartis

Phase 3 Completed
235 enrolled 23 charts

Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡